Effective therapies against overwhelming Gram-negative bacteremia, or sepsis, have eluded successful development. The discovery that tumor necrosis factor (TNF), a host-derived inflammatory mediator, was both necessary and sufficient to recapitulate Gram-negative sepsis raised cautious optimism for developing a targeted therapeutic. However, the rapid kinetics of the TNF response to infection defined an extremely narrow window of opportunity during which anti-TNF therapeutics could be successfully administered. HMGB1 was previously studied as a DNA-binding protein involved in DNA replication, repair, and transcription; and as a membrane-associated protein that mediates neurite outgrowth. A decade-long search has culminated in our identification of HMGB1 as a late mediator of endotoxemia. HMGB1 is released by macrophages upon exposure to endotoxin, activates many other proinflammatory mediators, and is lethal to otherwise healthy animals. Elevated levels of HMGB1 are observed in the serum of patients with sepsis, and the highest levels were found in those patients that died. The delayed kinetics of HMGB1 release indicate that it may be useful to target this toxic cytokine in the development of future therapies.
INTRODUCTION
Endotoxin, a lipopolysaccharide produced by all Gramnegative bacteria, is the most widely studied bacterial toxin. Endotoxin is lethal to mammals because it induces cells of the innate immune system, primarily macrophages and neutrophils, to release factors that cause shock and tissue injury. These responses mimic the systemic effects of overwhelming bacterial infection, and offer a useful starting point for exploring the pathogenic responses, the mediators, and the pathological signaling pathways.
In assessing the role of a putative mediator, it is common to consider whether the etiological agent fulfils Koch's postulates, a logical chain of evidence that has been modified for the field of cytokine biology to develop proof of causality. For instance, TNF, a 17 kDa polypeptide cytokine, is a major product of the activated immune system, and fulfils Koch's postulates as a pathogenic mediator of Gram-negative septic shock. First, large amounts of TNF are produced during the early response to endotoxemia and Gram-negative bacteremia in mammals. Second, administration of TNF in the absence of bacteria to otherwise normal animals reproduces an acute disease state that is physiologically, metabolically, hematologically, and pathologically indistinguishable from Gram-negative septic shock or endotoxic shock. Third, removing the mediator from the diseased animals prevents the manifestations of the disease. This has been achieved either by treating bacteremic animals with neutralizing anti-TNF antibodies, or by gene knockout studies in which mice rendered devoid of either TNF itself or TNF receptors are protected against the lethality of endotoxin. Importantly, treatment of bacteremic baboons with anti-TNF antibodies can suppress the activation of downstream cytokine cascades (e.g. IL-1, IL-6), indicating that the presence of bacteria in the bloodstream is not sufficient to activate the release of other pathogenic mediators. Rather, TNF is in fact both necessary and sufficient to elicit direct pathological responses and downstream, or 'late' cytokine cascades. The rapidly pathogenic nature of TNF has unfortunately hampered the development of effective anti-TNF therapeutics to treat sepsis because it is difficult to administer the agent early enough in the course of infection to provide uniform protection in the majority.
Even though TNF was the first mediator that fulfilled Koch's postulates in lethal endotoxic shock, its early and transient activity make it an impractical therapeutic target for sepsis. Several observations prompted us to search for other, more amenable targets. For instance, lethal endotoxemia kills animals hours or days after the early TNF peak activity resolves. Moreover, high doses of endotoxin kill genetically engineered TNF knockout animals, again after several hours or days. Accordingly, nearly a decade ago we set out to identify a putative 'late-acting' mediator of endotoxin lethality that could mediate lethality distinct from TNF. At that time, the hope was that targeting such a mediator might expand the window of opportunity for administering a therapeutic agent to septic patients. The outcome of this search led to the recent identification of high mobility group protein-1 (HMGB1) as a late mediator of endotoxin lethality. The function of this ubiquitous, highly conserved DNA-binding nuclear protein was previously ascribed to roles in DNA transcription, replication and repair, as well as cell motility and neurite outgrowth. Newly emerging data now indicate that when HMGB1 is released by a stimulated innate immune system, it functions as a cytokine and participates in the development of the lethal toxicity of endotoxin. Like other critically important cytokines, HMGB1 has multiple mediator activities (Table 1) including stimulating the release of other cytokines, amplifying the development of acute lung injury, and causing death.
THE HIGH MOBILITY GROUP PROTEINS
The high mobility group proteins, named originally for electrophoretic mobility properties on polyacrylamide gels were originally isolated by Johns in the early 1960s and characterized by chemical and physical properties. 1 HMGB proteins are among the most ubiquitous, abundant, and evolutionarily conserved proteins in eukaryotes. These proteins, and the other members of a larger HMG superfamily, share a common structural motif, termed the 'HMG box', which is a unique, ~80 residue, L-shaped domain that mediates DNA binding (reviewed by Bustin & Reeves 2 ). Phylogenetic studies of proteins bearing the HMG box have revealed that >120 proteins, from protozoans to humans, share this motif. 3 Proteins bearing HMG boxes are divided into two groups based on the number of HMG boxes in the protein. The first group has two or more HMG boxes, and includes the founding members, HMGB1 and HMGB2, the RNA polymerase I transcription factor UBF, members of the V(D)J recombinase, and the mitochondrial transcription factors mtTF and ABF2. 2, 4, 5 The second group contains proteins bearing a single HMG box, and includes DNA structure-specific binding proteins, non-histone chromatin-binding proteins, and a number of transcription factors. [6] [7] [8] [9] [10] [11] This review is focused on members of the first group.
The HMGB family
The HMGB proteins have molecular weights of approximately 25-30 kDa and share 80% amino acid identity within higher eukaryotic species (reviewed by Bustin et al. 12 ). HMGB1 and HMG-2 are encoded by separate genes. 13, 14 In mice, the HMGB1 gene resides on chromosome 5, 15 while in humans the gene lies on chromosome 316 Czura, Wang, Tracey [19] [20] [21] HMGB1 is reversibly acetylated on internal lysine residues, 22 a post-translational modification that is influenced by spermine, dexamethasone, and hormones. 23, 24 HMGB1 acetylation has been implicated in influencing chromatin structure, and may be required for participation in DNA replication and transcription. [25] [26] [27] Histone N-acetyltransferase can acetylate sites within HMGB1 that are structurally similar to acetylation sites in histones, even though HMGB1 binds the enzyme with lower affinity. 27 HMG proteins can also be subjected to phosphorylation, methylation, 1 and ADP-ribosylation. 28 The consequences of HMGB1 binding DNA HMGB1 binds either double-stranded or single-stranded DNA, and has an affinity for a variety of non-B DNA structures, including four-way junctions, bent DNA, and DNA adducts. HMGB1 binds double-stranded DNA in the minor groove in a sequence-independent manner that covers approximately 14 bases or pairs. 2,29 HMGB1 induces DNA bending 30-32 that facilitates gene expression or DNA replication by allowing the formation of large, multi-protein complexes. 2 For example, recent studies have revealed the functional importance of the protein-protein interaction between HMGB1 and the progesterone receptor, and protein-minor groove interactions between HMGB1 and the progesterone response element. 30, 33 Similar mechanisms operate for other steroid receptors, including the estrogen, androgen, and glucocorticoid receptors. 34, 35 Together, these studies indicate that HMGB1 participates in establishing the structural framework and geometric requirements necessary for the function of some transcription factors. [36] [37] [38] HMGB1 may also facilitate formation of the pre-initiation complex (PIC) by recruiting transcriptional activators, 39 including steroid hormone receptors, 30, [33] [34] [35] USF, 40 Hox proteins, 38 Oct transcriptional activators, 41 and p53. 42 The Drosophila homolog of HMGB1 (termed 'DSP-1'), binds Rel65, the fly counterpart to NF-κB, 43 and like other protein-protein interactions of HMGB1, can participate in mediating signals through its third, C-terminal domain, which is not involved in DNA interactions. 44 
Membrane-associated HMGB1 or 'amphoterin'
In the late 1980s, studies of rat brain identified an extracellular protein that was developmentally regulated and induced the outgrowth of neurite-like cytoplasmic processes in cultured brain and neuroblastoma cells. 45 The heparin binding protein was originally termed 'p30' because it had an apparent molecular weight of 30 kDa on SDS-PAGE. 45 Sequence studies revealed that p30 had a highly charged, dipolar structure, inspiring a new name, 'amphoterin'. 46 The 214 amino acids of 'amphoterin' were highly homologous to the 259 amino acids of HMGB1 originally isolated from calf thymus. 46 In fact, a GenBank search has revealed that the sequence of rat 'amphoterin' and all of the sequences of rat HMGB1 are identical, and that human HMGB1 is 99% identical to the rat protein. In the C terminal tail, there are two conservative amino acid substitutions: an aspartic acid is replaced by glutamic acid at position 189 in the human protein, and a glutamic acid is replaced by as aspartic acid at position 202. HMGB1 ('amphoterin') can mediate cellular outgrowth by interaction with the receptor for advanced glycation end-products, RAGE. RAGE is a protein member of the immunoglobulin superfamily that is homologous to a neural cell adhesion molecule 47 and is expressed early in the development of the central nervous system. HMGB1 ('amphoterin') has been identified as a specific and saturable ligand for RAGE that binds with high affinity. 48 Colocalization of RAGE and HMGB1 at the leading edge of advancing neurites has implicated this interaction in cell migration during development. 48 This HMGB1/RAGE interaction may occur in tumor formation as well because blocking this interaction can decrease the growth and metastasis of both implanted and spontaneous tumors. 49 HMGB1-induced intracellular signaling through RAGE can activate two cascades, one involving Rac and Cdc42 leading to cytoskeletal re-organization, and a second that involves Ras and activates NF-κB. 50 The expression of RAGE is mediated, at least in part, through an auto-regulatory loop, whereby the interaction of HMGB1 with RAGE leads to the NF-κB-and Sp1-dependent transactivation of the RAGE gene. [51] [52] [53] HMGB1 as a late mediator of endotoxin lethality HMGB1 was rediscovered during our search for a mediator of endotoxin lethality that was released as a 'late' product of endotoxin-stimulated macrophages. We found that HMGB1 was released as a soluble, biologically active mediator from macrophage cultures exposed to endotoxin (lipopolysaccharide, LPS) for 8 h or more. 54 A similar kinetic release pattern was observed in pituicyte cultures, which also released HMGB1 into the culture media after stimulation with TNF and IL-1. As with other macrophage-derived mediators, HMGB1 release was significantly enhanced by the addition of IFN-γ, but IFN-γ alone failed to activate HMGB1 release. 55 Like other cytokines, including TNF, IL-1 and macrophage migration inhibitory factor (MIF), HMGB1 lacks a conventional hydrophobic secretion signal peptide, 56 and the mechanism of its LPS-stimulated release is enigmatic. Pulse-labeling experiments revealed that HMGB1 released during the first 12 h after endotoxin exposure was derived predominantly from preformed pools. Human peripheral blood mononuclear cells (PBMC) and primary macrophages from LPS-sensitive mice also released HMGB1 in response to LPS. This release was specific because human primary T cells, rat adrenal cells, rat primary kidney cells, and macrophages derived from LPS-resistant C3H/HeJ mice did not release HMGB1 after stimulation with LPS. 54 The prototypical inflammatory mediators TNF and IL-1 are released within minutes of LPS administration, attain peak levels within a few hours, then return to low basal levels within 8-10 h. In contrast, the late secretion of HMGB1 (8-20 h), and the activation of HMGB1 release by TNF and IL-1, make it plausible to consider that pro-inflammatory mediators in addition to LPS can function as upstream regulators of HMGB1 release. In LPS-sensitive mice, LPS induced the release of detectable levels of HMGB1 into the serum within 8 h, and was maintained at peak levels from 16-32 h. Analyses revealed that the concentration of HMGB1 in the serum was roughly equivalent to the amounts of TNF and IL-1 produced during lethal endotoxemia. 54 To address whether the accumulation of HMGB1 in lethal endotoxemia was injurious or beneficial, mice were passively immunized with anti-HMGB1 antibodies. Antibody treatment conferred a highly significant, dose-dependent, lasting protection against lethal doses of LPS. Significant protection was observed even when the first doses of antibodies were given after the TNF peak had resolved, indicating that it may be reasonable to target this mediator through a wider therapeutic window.
The toxicity of HMGB1 itself was studied by administration of rHMGB1, and doses as low as 250 µg/mouse were lethal to both LPS-sensitive and LPS-resistant mice. 54 Intratracheal administration of HMGB1 produced a dosedependent increase in neutrophil accumulation in the lung. 57 This was accompanied by elevated levels of other proinflammatory mediators (IL-1β, TNF, and MIP-2), even when HMGB1 was given in doses as low as 1 µg/mouse. Histological examination of HMGB1-exposed lungs showed acute infiltration of neutrophils into the interstitial and intraaveolar areas, interstitial edema, and protein accumulation in the alveolar space. These pathological effects, which are similar to the response to intratracheal endotoxin administration, could be significantly inhibited by passive immunization of endotoxin treated mice with anti-HMGB1 antibodies. The protection conferred by anti-HMGB1 did not significantly alter the LPS-induced levels of IL-1β, TNF, and MIP-2, indicating that HMGB1 acts as a distal mediator of endotoxininduced pulmonary inflammation. 57
HMGB1 is a cytokine
The observations that even low doses of HMGB1 were associated with fever, weight loss, pilo-erection, shivering, 54 microthrombi formation in the lungs, 57 reduced food intake, weight loss, 58 endotoxin lethality, and its release from endotoxin-stimulated macrophages 54 indicate that secreted HMGB1 is a cytokine. 59 Other pro-inflammatory mediators of endotoxemia also stimulate the release of cytokines from monocytes, thereby amplifying and extending the 'cytokine cascade'. [60] [61] [62] [63] [64] Like these other cytokines, addition of HMGB1 to monocyte cultures dose-dependently stimulated the release of cytokines, even in concentrations that are comparable to stimulating concentrations of LPS (100 ng/ml). 65 These small doses of HMGB1, that are well within the pathological range previously observed in endotoxemic animals, 54 significantly stimulated the release of TNF, IL-1α, IL-1β, IL-1RA, IL-6, IL-8, and MIP-1β. This effect was specific, as other cytokines, including IL-12 and the anti-inflammatory cytokine IL-10, were not up-regulated, and the inducible cytokine response was limited to monocytes. 65 Notably, the kinetics of cytokine release from HMGB1-stimulated monocytes were incompatible with those of LPS administration because HMGB1-induced cytokine release was delayed 1-4 h as compared to LPS alone. 65 
Clinical measurements of HMGB1
Levels of HMGB1 in the serum of healthy volunteers are undetectable, but HMGB1 is significantly elevated in the serum of critically ill septic patients; the highest levels were observed in those patients that eventually succumbed. 54 Elevated serum HMGB1 concentrations have also been identified in a patient suffering from hemorrhagic shock in the absence of any detectable infection; the patient's recovery during a 96 h course after shock was associated with a nomalization of serum HMGB1 levels. 66 
CONCLUSIONS
HMGB1 is a widely studied DNA binding protein that can be released during activation of the innate immune system. It can bind specifically to human monocytes (H. Yang & K. Tracey, unpublished observations) and induce the secretion of pro-inflammatory cytokines. 54, 65 Receptor/ligand interaction with RAGE may activate macrophages, 67, 68 but it is also plausible to consider that HMGB1 can significantly increase the cellular uptake of extracellular DNA, 69, 70 and that it may interact with another receptor(s). Another possibility is that HMGB1 secreted from monocytes may directly activate transcription after signaling through direct protein-protein or protein-DNA interactions in the nuclei of target cells. As a late mediator of endotoxin lethality, it appears that this newly identified cytokine can participate in propagating and amplifying downstream inflammatory responses. Like other pro-inflammatory cytokines, it is likely that there are as yet unidentified protective roles for secreted HMGB1 that are advantageous to the infected host. Additional preclinical trials in models of on-going infection are needed in order to clarify and bolster the definition of a cytokine role for HMGB1 in sepsis, hemorrhagic shock, and acute lung injury. Because it acts as a late mediator of endotoxin lethality, targeting HMGB1 therapeutically may significantly broaden the window of opportunity in which septic patients can be successfully treated.
